A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.

NCT07280858 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

368

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants
Sarbecovirus

Interventions

BIOLOGICAL: Test Drug 1-1 (GBP511 low dose)
BIOLOGICAL: Test Drug 1-2 (GBP511 mid dose)
BIOLOGICAL: Test Drug 1-3 (GBP511 high dose)
BIOLOGICAL: Test Drug 2-1 (GBP511 low dose + CAS-1)
BIOLOGICAL: Test Drug 2-2 (GBP511 mid dose + CAS-1)
BIOLOGICAL: Test Drug 2-3 (GBP511 high dose + CAS-1)
BIOLOGICAL: Comparator (Comirnaty)
BIOLOGICAL: Placebo (Normal Saline)
BIOLOGICAL: Test Drug 13 (Stage 2, GBP511-A or B)
BIOLOGICAL: Test Drug 14 (Stage 2, GBP511-A or B)

Sponsor

SK Bioscience Co., Ltd.